Articles By RheumNow
Interferon Blocker Disappoints in SLE
By RheumNow
Yet another setback has occurred in the efforts to develop new medications for treating systemic lupus erythematosus (SLE), as anifrolumab failed to meet the primary endpoint in a phase III trial, according to AstraZeneca and MedImmune.
Read Article
Sleep Apnea Raises Gout Risk
By RheumNow
Patients with obstructive sleep apnea were at increased risk for incident gout, particularly in the first years after the sleep apnea diagnosis, U.K. researchers reported.
Read ArticleQuestions Remain about Shingrix Safety in Rheumatic Disease
By RheumNow
The efficacy and safety of the new zoster vaccine Shingrix has not been established among patients with autoimmune diseases, researchers reported here.
Read ArticleEarly Exposure to Passive Smoke May Up Risk for RA Later in Life
By RheumNow
Exposure to second-hand smoke during childhood was associated with an increased risk for developing rheumatoid arthritis (RA) later in life, researchers said.
Read Article
Success of Stopping Depends on the Biologic
By RheumNow
The type of biologic disease-modifying anti-rheumatic drug (DMARD) being used and remission duration were important factors predicting whether remission was maintained among patients with rheumatoid arthritis after cessation of the biologic, a Japanese study found.
Read Article
Big Advances for Two Osteoporosis Drugs
By RheumNow
New developments with the FDA and new scientific findings are adding momentum to two drugs experts believe are game-changers in osteoporosis treatment.
Read Article
Ethnicity Matters in Sjogren's Syndrome
By RheumNow
Among the ethnically diverse residents of Manhattan, certain groups had markedly different incidence rates of primary Sjogren's syndrome, a retrospective study found.
Read Article
IL-1 Suppression May Improve Dilated Cardiomyopathy
By RheumNow
Interleukin-1 (IL-1) suppression helped reverse symptoms of dilated cardiomyopathy (DCM) for one patient in a case study that may implicate inflammation in the development of the condition.
Read Article
Minimal Disease Activity: The Goal in PsA
By RheumNow
The majority of patients with psoriatic arthritis (PsA) who achieved a state of minimal disease activity (MDA) after 6 months of treatment with adalimumab (Humira) maintained that response through 24 months, a large observational study found.
Read Article
The Lung in RA: Little Progress
By RheumNow
The progress that has been seen in the management of many aspects of rheumatoid arthritis (RA) has not been paralleled for the pulmonary disease that remains the second most common cause of death among these patients, an Australian expert reported here at the annual meeting of the Florida Society
Read Article